<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26413" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Osteoporosis in Spinal Cord Injuries</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Varacallo</surname>
            <given-names>Matthew</given-names>
          </name>
          <aff>Penn Highlands Healthcare System</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Davis</surname>
            <given-names>Donald D.</given-names>
          </name>
          <aff>Wellstar Atlanta Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pizzutillo</surname>
            <given-names>Peter</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Matthew Varacallo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Donald Davis declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Peter Pizzutillo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26413.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Osteoporosis is a condition describing a spectrum of overall compromised skeletal microarchitecture with clinical manifestations related to decreasing levels of bone mineral density (BMD). Spinal cord injuries (SCIs) vary significantly in terms of the range of clinical impact and overall compromise to a patient's functional outcomes and quality of life. SCIs have long been recognized as a clinical culprit that ultimately leads to osteoporosis. Clinicians are encouraged to recognize and appreciate the similarities and subtle nuances differentiating SCI-induced osteoporosis as a separate and distinct clinical sub-entity of the broader more generalized osteoporosis diagnosis. This activity reviews the etiology, presentation, evaluation, and management of spinal cord injuries and osteoporosis, and reviews the role of the interprofessional team in evaluating, diagnosing, and managing the condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the basic pathophysiology of osteoporosis resulting from spinal cord injury.</p></list-item><list-item><p>Discuss the diagnostic workup for a patient presenting with osteoporosis secondary to spinal cord injury.</p></list-item><list-item><p>Review the treatment, management, and prognosis of osteoporosis resulting from SCI.</p></list-item><list-item><p>Summarize the significance of coordination among the members of the interprofessional team in providing improved care leading to optimal outcomes for patients with osteoporosis secondary to spinal cord injury.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26413&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26413">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26413.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Osteoporosis is a condition describing a spectrum of overall compromised skeletal microarchitecture with clinical manifestations related to decreasing levels of bone mineral density (BMD).<xref ref-type="bibr" rid="article-26413.r1">[1]</xref>,<xref ref-type="bibr" rid="article-26413.r2">[2]</xref>&#x000a0;Spinal cord injuries (SCIs) vary significantly in terms of the range of clinical impact and overall compromise to a patient&#x02019;s functional outcomes and quality of life. SCIs have long been recognized as a clinical culprit that ultimately leads to osteoporosis.<xref ref-type="bibr" rid="article-26413.r3">[3]</xref>&#x000a0;Clinicians are encouraged to recognize and appreciate the similarities and subtle nuances differentiating SCI-induced osteoporosis as a separate and distinct clinical sub-entity of the broader more generalized osteoporosis diagnosis.</p>
      </sec>
      <sec id="article-26413.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>SCIs involve a classic bimodal distribution pattern.<xref ref-type="bibr" rid="article-26413.r4">[4]</xref></p>
        <p>Younger patients are injured via high-energy mechanisms with the following approximate associated incidence rates<xref ref-type="bibr" rid="article-26413.r4">[4]</xref>,<xref ref-type="bibr" rid="article-26413.r5">[5]</xref>,<xref ref-type="bibr" rid="article-26413.r6">[6]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Motor Vehicle Accidents - 50% to 75%</p>
          </list-item>
          <list-item>
            <p>Falls - 10% to 15%</p>
          </list-item>
          <list-item>
            <p>Gunshot wounds - 10% to 15%</p>
          </list-item>
          <list-item>
            <p>Sports - 10% to 15%</p>
          </list-item>
          <list-item>
            <p>Iatrogenic - estimated incidence ranges from 3% to 25% of all SCIs occurring secondary to improper immobilization and patient transport</p>
          </list-item>
        </list>
        <p>The elderly patient population sustains the majority of SCIs via minor trauma or mechanical falls. Elderly patients are predisposed to injury secondary to an underlying degenerative spine and associated spinal stenosis.<xref ref-type="bibr" rid="article-26413.r6">[6]</xref></p>
      </sec>
      <sec id="article-26413.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The prevalence of SCIs in the United States (US) increased by 30% from 1994 to 2012<xref ref-type="bibr" rid="article-26413.r3">[3]</xref>&#x000a0;In 2016, it was estimated that approximately 17,000 new SCI cases occurred in the US alone, representing an annual incidence of 54 cases per million population.<xref ref-type="bibr" rid="article-26413.r4">[4]</xref>&#x000a0;The prevalence of osteoporosis in the US is 10 million, with an additional 34 million considered to be at-risk and given a diagnosis of osteopenia, a term used to describe patients with BMD levels between that of normal reference range values but not low enough to be diagnostically considered osteoporotic.<xref ref-type="bibr" rid="article-26413.r2">[2]</xref></p>
        <p>These aforementioned epidemiologic trends and patterns merge to result in over 50% of patients with a complete SCI developing osteoporosis by 1 year after the injury.<xref ref-type="bibr" rid="article-26413.r7">[7]</xref>&#x000a0;Long-term follow-up&#x000a0;increases the prevalence rate to greater than 80%.<xref ref-type="bibr" rid="article-26413.r7">[7]</xref>&#x000a0;However, the most devastating complication secondary to osteoporosis developing after an SCI is the fragility fracture. Over half of these patients at long-term follow-up will sustain at least one low-impact fracture at some point&#x000a0;after the SCI.<xref ref-type="bibr" rid="article-26413.r3">[3]</xref></p>
      </sec>
      <sec id="article-26413.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>
<bold>Disuse Osteoporosis and Osteopenia</bold>
</p>
        <p>Patients sustaining SCIs are predisposed to disuse osteopenia from prolonged immobilization and overall decreased mobility and independent functional capabilities. Normal bone physiology relies on a process of active remodeling in a constant cycle of bone formation and bone resorption. In SCI, the generalized loss of mobility and ability to perform normal weight-bearing activities of daily living eventually uncouples the active remodeling process. The first 2 weeks after the initial injury is recognized as the most vulnerable period for decreased bone formation.<xref ref-type="bibr" rid="article-26413.r8">[8]</xref></p>
        <p>
<bold>Sclerostin, Vitamin D, P</bold>
<bold>arathyroid Hormone</bold>
</p>
        <p>Recent studies suggest that sclerostin plays a critical role in SCI-induced bone loss. Sclerostin is produced&#x000a0;primarily&#x000a0;by osteocytes and inhibits bone formation via multiple mechanisms, including the up-regulation of receptor activator of nuclear factor-kappa B ligand (RANKL) and down-regulation of osteoprotegerin (OPG).<xref ref-type="bibr" rid="article-26413.r9">[9]</xref>&#x000a0;The end&#x000a0;result of these pathways yields a net increase in bone resorption.&#x000a0;</p>
        <p>Several studies have demonstrated increased levels of sclerostin in patients afflicted with clinical conditions resulting in disability and immobility. In addition to SCI patients, stroke patients are considered particularly&#x000a0;vulnerable and at risk for acute and chronic compromise to BMD levels. Moreover, sclerostin levels appear to be highest during the initial post-injury phase, followed by decreasing levels detected in chronic SCI osteoporosis patients.<xref ref-type="bibr" rid="article-26413.r3">[3]</xref></p>
        <p>SCI patients typically have abnormally low levels of vitamin D and parathyroid hormone (PTH) levels in both the acute and chronic phases of SCI injury and recovery.&#x000a0; Acutely, PTH levels are low secondary to the initial hypercalcemia resulting from the sclerostin-induced bone resorption.<xref ref-type="bibr" rid="article-26413.r3">[3]</xref></p>
        <p>
<bold>Long-Term Implications</bold>
</p>
        <p>After the initial 2 weeks following SCI, studies have suggested that, while bone formation rates can return to normal levels, the regions of the body below the level of the lesion (i.e., sublesion levels) continue to experience a 4% per month reduction in BMD.&#x000a0; In addition, trabecular BMD is decreased by 40% by 2 years after the injury. Similarly, the long bones in the lower extremity undergo appreciable cortical thinning following SCI, predisposing to low-energy impact fractures.<xref ref-type="bibr" rid="article-26413.r10">[10]</xref></p>
        <p>Beyond 2 to 5 years post-SCI,&#x000a0;controversy&#x000a0;remains in the literature with respect to ongoing decremental BMD rates into perpetuity. Some reports suggest that bone loss plateaus after 3 to 5 years, while others demonstrate a steady decremental loss in BMD.<xref ref-type="bibr" rid="article-26413.r3">[3]</xref></p>
        <p>
<bold>Fragility Fractures</bold>
</p>
        <p>SCIs represent conditions of significant morbidity and mortality.&#x000a0; With respect to osteoporosis, the most obvious and devastating clinical manifestation is the fragility fracture.<xref ref-type="bibr" rid="article-26413.r1">[1]</xref>&#x000a0;The initial rapid decrease in BMD levels, even in the youngest of patients, can yield multiple ensuing fragility fractures. It is worth noting that many of these fractures can occur spontaneously, leading to missed or delayed diagnoses.<xref ref-type="bibr" rid="article-26413.r3">[3]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-26413.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histologic osteoporotic specimens demonstrate thinning of the trabeculae, decreased osteon size, and enlarged haversian and marrow spaces.<xref ref-type="bibr" rid="article-26413.r11">[11]</xref></p>
      </sec>
      <sec id="article-26413.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>History</bold>
</p>
        <p>Clinicians should first consider the presentation of the patient with a history of SCI and note the time that elapsed between the present clinical evaluation and the original index injury. As mentioned earlier, the first 2 weeks after the SCI represents the most vulnerable time period for rapid decreases in BMD levels.</p>
        <p>As part of a comprehensive history, the clinician should also consider predisposing&#x000a0;conditions and the patient&#x02019;s age; these could potentially compound conditions of already compromised BMD levels. For example, elderly patients presenting 2 weeks after an SCI&#x000a0;were&#x000a0;likely previously&#x000a0;diagnosed with osteoporosis or osteopenia before the injury. In effect, these patients are at the highest risk of developing spontaneous fractures without an appreciable underlying mechanism.</p>
        <p>Other pearls for history taking include the following<xref ref-type="bibr" rid="article-26413.r1">[1]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>History of fragility fractures (e.g., hip fractures, vertebral compression fractures)</p>
          </list-item>
          <list-item>
            <p>Predisposing chronic medical conditions (e.g., eating disorders, asthma, malignancy, inflammatory conditions, endocrinopathies, malnutrition states)</p>
          </list-item>
          <list-item>
            <p>Medication use (e.g., anti-seizure medications, chronic steroid use, proton-pump inhibitors, methotrexate)</p>
          </list-item>
          <list-item>
            <p>History of early menopause or current post-menopausal status for female patients</p>
          </list-item>
          <list-item>
            <p>History of anti-osteoporosis medication treatment(s)</p>
          </list-item>
        </list>
        <p>A comprehensive history includes eliciting potential risk factors attributable to secondary bone loss. A thorough social history&#x000a0;also&#x000a0;should be obtained with attention to smoking history and chronic alcohol consumption. The physician should note the patient&#x02019;s presenting overall nutritional status as well as any ongoing or previous calcium and/or vitamin D supplementation. A family history of osteoporosis&#x000a0;also&#x000a0;should be noted. The patient should be asked about any prior fractures, with focus given to low-energy ground-level fall mechanisms and any fractures after the age of 40.<xref ref-type="bibr" rid="article-26413.r2">[2]</xref>&#x000a0;Studies have demonstrated greater trabecular deterioration in post-menopausal women with a complete SCI compared to post-menopausal, ambulatory women.<xref ref-type="bibr" rid="article-26413.r2">[2]</xref></p>
        <p><bold>Physical Exam</bold><xref ref-type="bibr" rid="article-26413.r12">[12]</xref>,<xref ref-type="bibr" rid="article-26413.r13">[13]</xref></p>
        <p>Patients with SCI will present with varying clinical pictures, depending on the level of the injury. The clinician should note the specific injury type and classification. Descriptive categories include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Paraplegia
<list list-type="bullet"><list-item><p>SCI causing dysfunction from the trunk/pelvic regions to the lower extremities</p></list-item><list-item><p>Patients have spared upper extremity function which preserves varying levels of independent mobility</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tetraplegia</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>SCI injuries at the level of the cervical spine, leading to dysfunction of the upper extremities, trunk/pelvic regions, and lower extremities</p>
              </list-item>
              <list-item>
                <p>Patients are particularly&#x000a0;susceptible to progressive losses in BMD as well as spontaneous VCFs without an apparent mechanism</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Complete SCI</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Patient is diagnosed with a complete SCI in the acute setting after resolution of the spinal shock state (i.e., after the return of the patient&#x02019;s bulbocavernosus reflex)</p>
              </list-item>
              <list-item>
                <p>Patients have no spared motor or sensory function below the defined level of injury (i.e., American Spinal Injury Association [ASIA] A injuries)</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Incomplete SCI</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Injuries are subdivided into syndromes of clinical manifestation based on the anatomic area of injury to the spinal cord</p>
              </list-item>
              <list-item>
                <p>All of these syndromes demonstrate some preserved motor or sensory function below the defined level of injury</p>
              </list-item>
              <list-item>
                <p>Syndromes include&#x000a0;the following:</p>
              </list-item>
              <list-item>
                <list list-type="bullet">
                  <list-item>
                    <p>Anterior cord&#x000a0;</p>
                  </list-item>
                  <list-item>
                    <p>Posterior cord&#x000a0;</p>
                  </list-item>
                  <list-item>
                    <p>Central cord&#x000a0;</p>
                  </list-item>
                  <list-item>
                    <p>Cauda equina&#x000a0;</p>
                  </list-item>
                  <list-item>
                    <p>Conus medullaris&#x000a0;</p>
                  </list-item>
                  <list-item>
                    <p>Brown-Sequard</p>
                  </list-item>
                </list>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>In addition to documenting a comprehensive motor and sensory exam, careful palpation and heightened clinical suspicion for spontaneous/occult fractures are critical. The most common location for spontaneous fractures is in the sublesion regions, especially the lower extremity long bones.<xref ref-type="bibr" rid="article-26413.r14">[14]</xref>&#x000a0;The clinician should note any focal or diffuse areas of swelling, including deformity and overall limb alignment.</p>
        <p>Much attention should be given to the patient sustaining a fragility fracture, and early follow-up with an appropriate practitioner is highly encouraged to initiate treatment. Unfortunately, osteoporosis follow-up rates, even after fragility fractures have occurred, remain relatively low. Automated follow-up systems and fracture liaison services are two increasingly popular strategies to help improve on the historically reported and strikingly low follow-up rates of 1% to 10%.<xref ref-type="bibr" rid="article-26413.r15">[15]</xref></p>
      </sec>
      <sec id="article-26413.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>In general, osteoporosis follow-up trends and patterns have received increasing attention over the last 5 to 10 years, but SCI-induced osteoporosis follow-up patterns and treatment recommendations lag behind&#x000a0;that of the more generalized osteoporosis diagnostic category.&#x000a0; These issues are further propagated secondary to the overall complexity of the SCI injury in addition to those previously mentioned and notoriously low follow-up rates for treatment of osteoporosis&#x000a0;in general.</p>
        <p><bold>Osteoporosis Evaluation</bold><xref ref-type="bibr" rid="article-26413.r1">[1]</xref>,<xref ref-type="bibr" rid="article-26413.r2">[2]</xref></p>
        <p>The WHO has established dual-energy x-ray absorptiometry (DXA) scans as the gold standard for assessing BMD levels. DXA&#x000a0;scans utilize an x-ray beam to measure calcified tissue in targeted regions in the body. DXA scans are reported to be the most accurate diagnostic imaging modality with the least amount of radiation exposure. The lumbar spine (L2 to L4), the hip (compiled from the femoral neck, trochanters, and intertrochanteric regions), and the wrist are routinely included in the scan. The BMD reported reflects the absolute, patient-specific score determined from these measured anatomic areas.&#x000a0;</p>
        <p>In addition, the scan also reports a t-score and a z-score.&#x000a0; The t-score is measured in standard deviations and reflects the difference between the patient's measured BMD and the mean value of BMD in healthy, young, matched controls (e.g., 30-year-old women). By definition, a normal BMD measurement is within one standard deviation of the young adult mean. The WHO defines t-scores between -1 and -2.5 as osteopenic and scores below -2.5 as osteoporotic. The z-score&#x000a0;is also measured in standard deviations, but the z-score is compared to a healthy, age-matched control group. The z-score is most clinically relevant when obtaining a DXA scan in younger patients when secondary osteoporosis is being considered. A z-score less than -1.5 warrants a comprehensive secondary osteoporosis workup.</p>
        <p>Standard laboratory workup includes checking calcium, phosphorus, albumin, alkaline phosphatase, liver function tests, creatinine (serum and urine), 25 hydroxyvitamin D, thyroid-stimulating hormone (TSH) and free T4, and intact parathyroid hormone (PTH) levels. Males should have a free testosterone level checked to rule out hypogonadism.&#x000a0;</p>
        <p>The routine use of checking bone turnover markers (BTM) is debated. The utility of obtaining markers of bone resorption can be considered if it is being considered the possible underlying cause of secondary osteoporosis. Although reports question the reproducibility of such values, available tests include checking serum or urinary cross-links of type I collagen (deoxypyridinoline), N-telopeptide of type I collagen (NTx), or C-telopeptide of type I collagen (CTx).</p>
        <p>The WHO created a fracture risk assessment tool (FRAX score) to predict the 10-year risk of sustaining a hip or other major osteoporotic fracture. These other major fragility fractures include fractures of the spine, wrist, forearm, or humerus. The assessment includes 12 questions weighted by the relative risk associated with a future fragility fracture event. Assessment includes age, sex, personal history of fracture, low BMI, oral steroid use, secondary osteoporosis, parental history of hip fracture, smoking status, and alcohol intake. In addition, optional BMD measurement values can be included from a prior DXA scan (if available) to provide a more comprehensive score report.&#x000a0;</p>
        <p>The utility of the FRAX score is emphasized, especially in the osteopenic patient. Although fracture risk increases with decreases in BMD, the concept that the vast majority of these fragility fractures occur in osteopenic (as opposed to osteoporotic) patients poses a conflicting treatment paradigm. Thus, clinicians rely on the FRAX score to stratify which osteopenic patients exceed the risk threshold to warrant more aggressive pharmacologic treatments.&#x000a0;<xref ref-type="bibr" rid="article-26413.r16">[16]</xref>,<xref ref-type="bibr" rid="article-26413.r17">[17]</xref></p>
      </sec>
      <sec id="article-26413.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Clinicians are encouraged to recognize the similarities and subtle differences when managing osteoporotic patients versus SCI-induced osteoporotic patients. While some&#x000a0;general underlying principles in treatment exist, there is an evolving treatment paradigm to be recognized in the SCI-induced osteoporosis subgroup of patients.</p>
        <p>
<bold>Mechanical Loading</bold>
</p>
        <p>Weight-bearing activity stimulates and creates an ideal stress environment to promote physiologic bone remodeling according to the Wolff law. Mechanical loading has demonstrated reversal capabilities in the SCI-induced osteoporotic process in long bones in the lower extremity. Specifically, cortical thickening is noted in response to applied mechanical stress and strain even after disuse osteopenia has ensued. However, studies have demonstrated the most ideal environment to maximize osteogenic potential and create a net anabolic activity in bone turnover comes from intermittent force application. Constant stimulation can lead to desensitization of the bone to the applied mechanical forces.&#x000a0;<xref ref-type="bibr" rid="article-26413.r3">[3]</xref>,<xref ref-type="bibr" rid="article-26413.r17">[17]</xref></p>
        <p>
<bold>Vibration Therapy</bold>
</p>
        <p>Low magnitude mechanical signals (LMMS) as a therapeutic modality has demonstrated bone formation capabilities in both human and rodent models. However, beyond limited case reports there is little evidence available to advocate its definitive therapeutic potential.&#x000a0; Similarly, low-intensity vibration treatment protocols have shown some promising results in a small case series of SCI-induced osteoporotic patients.&#x000a0;<xref ref-type="bibr" rid="article-26413.r17">[17]</xref>,<xref ref-type="bibr" rid="article-26413.r18">[18]</xref></p>
        <p>
<bold>Calcium and Vitamin D</bold>
</p>
        <p>Without question, all patients should be taking calcium and vitamin D supplementation. Patients should be educated on the recommended daily intake for calcium and vitamin D. The National Osteoporosis Foundation (NOF) recommends 1200 to 1500 mg of calcium per day and 800 to 1000 IUs of daily vitamin D for adults over the age of 50. In the setting of SCI-induced osteoporosis, all patients should begin supplementation regardless of age at presentation.&#x000a0;<xref ref-type="bibr" rid="article-26413.r19">[19]</xref></p>
        <p>
<bold>Anti-Osteoporotic Pharmacotherapy Options</bold>
</p>
        <p>Pharmacotherapy agents work through either anti-resorptive or anabolic means. In general, bisphosphonates are the most commonly prescribed medication class for osteoporosis treatment. These drugs are divided into non-nitrogen and nitrogen-containing compounds. The latter are&#x000a0;considered&#x000a0;first-line therapy for osteoporosis.<xref ref-type="bibr" rid="article-26413.r2">[2]</xref>&#x000a0;However, a major concern with SCI-induced osteoporosis coupled with the bisphosphonate anti-resorptive mechanism on bone is the inability to actually demonstrate measurable increases in BMD levels.<xref ref-type="bibr" rid="article-26413.r3">[3]</xref></p>
        <p>In one study, alendronate was able to prevent further bone loss in 55 patients with chronic SCI-induced osteoporosis at the 2-year follow-up.&#x000a0; However, this is a stark contrast to alendronate&#x02019;s proven track record and documented capabilities to increase BMD values measured in ambulatory (i.e., not SCI-induced), post-menopausal women with osteoporosis.&#x000a0;<xref ref-type="bibr" rid="article-26413.r3">[3]</xref></p>
        <p>While alendronate, risedronate, and intravenous zoledronic acid have all demonstrated reduced fragility fracture rates in the general osteoporosis population, the clinical evidence has yet to be demonstrated in the SCI-induced osteoporosis population.<xref ref-type="bibr" rid="article-26413.r20">[20]</xref>&#x000a0;Clinicians are encouraged to recognize the subtle differences in efficacy and evidence-based approaches for the pharmacologic management of these vulnerable patients.</p>
        <p>
<bold>Denosumab</bold>
</p>
        <p>Denosumab, a monoclonal antibody against receptor activator of nuclear factor kappa-? ligand (RANKL), has recently been studied specifically in patients afflicted with SCI-induced osteoporosis. In 2016, one study demonstrated increases in lumbar and femoral BMD values as measured by DXA scans after 1 year of treatment compared to baseline BMD values. Denosumab was administered in a 60 mg every 6 months protocol during the study period.&#x000a0;<xref ref-type="bibr" rid="article-26413.r3">[3]</xref></p>
        <p>
<bold>Anabolic Agents and Emerging Pharmacotherapy Agents</bold>
</p>
        <p>Teriparatide is a recombinant form of PTH that stimulates osteoblasts to produce more bone. Teriparatide is now FDA approved for osteoporosis treatment in males and females, but more studies are needed in order&#x000a0;to improve our understanding of its effects on BMD levels and clinical outcomes in SCI-induced osteoporotic patients.&#x000a0;<xref ref-type="bibr" rid="article-26413.r18">[18]</xref>,<xref ref-type="bibr" rid="article-26413.r21">[21]</xref></p>
        <p>Activins are a group of agents belonging to the transforming growth factor-beta family and are highly expressed in bone. Studies have demonstrated that blocking the type II activin receptor, promotes bone formation secondary to the inhibition of activin A ligand signaling. In similar fashion, studies have also suggested the same conclusion when targeting cathepsin-K inhibitors. To date, there is little if any literature specifically targeting patients with SCI-induced osteoporosis. Future studies are warranted to delineate clinical efficacy.&#x000a0;<xref ref-type="bibr" rid="article-26413.r3">[3]</xref></p>
      </sec>
      <sec id="article-26413.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The key clinical elements to diagnosing SCI-induced osteoporosis include recognizing the time since the original SCI injury, establishing a baseline BMD value via a DXA scan, and following these patients closely to monitor the progression of bone loss. A relevant differential diagnosis pattern would entail initially categorizing a patient based on the bone loss spectrum via the established WHO criteria<xref ref-type="bibr" rid="article-26413.r19">[19]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Normal BMD = t-score of -1.0 or greater (i.e., within 1 standard deviation below normal, healthy control group reference values)</p>
          </list-item>
          <list-item>
            <p>Osteopenia = t-score between -1.0 and -2.5</p>
          </list-item>
          <list-item>
            <p>Osteoporosis = t-score below -2.5</p>
          </list-item>
        </list>
        <p>Also relevant in the differential diagnosis is considering underlying pre-existing medical conditions and medication use which may have already predisposed the patient to compromised BMD levels. Finally, always keep a heightened clinical suspicion for spontaneous fragility fractures, especially in the most compromised&#x000a0;patients with&#x000a0;SCI.</p>
      </sec>
      <sec id="article-26413.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Overall, the prognosis and decremental trend in BMD levels is worse compared to the general at-risk osteoporosis population</p>
          </list-item>
          <list-item>
            <p>By 1 year after the index SCI, over 50% of these patients will have osteoporosis</p>
          </list-item>
          <list-item>
            <p>Over 80% of chronic SCI patients develop osteoporosis</p>
          </list-item>
          <list-item>
            <p>Clinical efficacy and response to anti-osteoporosis treatment in these patients is less predictable compared to post-menopausal ambulatory women</p>
          </list-item>
        </list>
        <p>Also, note the following timeline for prognostic implications.</p>
        <list list-type="bullet">
          <list-item>
            <p>Two weeks following SCI: the patient at risk for rapid decreases in BMD levels</p>
          </list-item>
          <list-item>
            <p>Sublesion level bone loss: approximately 4% per month reduction in BMD can be expected</p>
          </list-item>
          <list-item>
            <p>Trabecular BMD bone loss: approximately 40% by 2 years after SCI injury</p>
          </list-item>
          <list-item>
            <p>Beyond 2 to 5 years post-injury: Controversy remains in the literature concerning ongoing decremental BMD rates into perpetuity. Some reports suggest that bone loss plateaus after 3 to 5 years, while others demonstrate chronic decreases in BMD.<xref ref-type="bibr" rid="article-26413.r3">[3]</xref>,<xref ref-type="bibr" rid="article-26413.r8">[8]</xref>,<xref ref-type="bibr" rid="article-26413.r22">[22]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26413.s12" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>The major complication of SCI-induced osteoporosis is the fragility fracture.<xref ref-type="bibr" rid="article-26413.r3">[3]</xref>,<xref ref-type="bibr" rid="article-26413.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>The majority of fragility fractures occur at the sublesion levels, especially long bones.<xref ref-type="bibr" rid="article-26413.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Many fragility fractures in patients with SCI occur spontaneously and can be missed or delayed in diagnosis.<xref ref-type="bibr" rid="article-26413.r10">[10]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26413.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>Patients with SCI should be immediately referred to a bone metabolic center, clinic, or establish early and regular care with an experienced physician capable of treating osteoporosis. Historically, follow-up rates for osteoporosis patients are notoriously low given the lack of a standardized care pathway. Treating physicians can include but are not limited to general practitioners, internists, endocrinologists, and/or some orthopedic surgeons.<xref ref-type="bibr" rid="article-26413.r2">[2]</xref>,<xref ref-type="bibr" rid="article-26413.r15">[15]</xref></p>
      </sec>
      <sec id="article-26413.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients with SCI should be educated about their acute and chronic risk of decremental BMD levels and the potential for low-impact fractures. Particularly, emphasis should focus on the initial and most vulnerable clinical window acutely following the SCI. The core treatment options for osteoporotic patients involve early education on how to achieve and maintain healthy bone mass levels and extensive education and counseling on the relevant social, environmental, and lifestyle risk factors that compromise bone health.<xref ref-type="bibr" rid="article-26413.r2">[2]</xref></p>
      </sec>
      <sec id="article-26413.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Osteoporosis secondary to spinal cord injury (SCI) presents a unique clinical subset of patients in the treatment of osteoporosis and at-risk patient populations. The care of these patients is optimized when a multifaceted and multi-phase approach is considered that involves nurses, pharmacists, and clinicians.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Acute SCI:</bold>&#x000a0;Initial presentation of the injured patient warrants diagnostic and treatment collaboration between the trauma team, spine surgeons (orthopedic surgery or neurosurgery), medical specialists, and intensive care physicians and nurses. The initial treatment phase should be given the utmost priority and will vary in terms of its complexity depending on the exact nature of the SCI.</p>
          </list-item>
          <list-item>
            <p><bold>Bone mineral density rapid progression phase:</bold>&#x000a0;During the initial 2 weeks following the acute SCI onset, physicians across all specialties must remain cognizant of the vulnerable period of rapid BMD loss. While knowledge of BMD losses over time in SCI-induced osteoporosis patients remains controversial, this acute phase would be a reasonable time to consult or refer the patient to a BMD-specialized clinic. Ideally, the clinic is experienced in initiating, managing, and following these patients over the long-term to combat the early onset of osteoporosis. The latter is especially imperative in younger patient populations.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Rehabilitation phases:</bold>&#x000a0;As these patients recover and rehabilitate over the long-term, equal attention should be given to the rehabilitation of the patient's overall mobility in addition to his or her overall bone health.&#x000a0;This&#x000a0;requires physical medicine and rehabilitation (PMR) clinicians, all physiotherapist-related personnel, and nurses caring for these patients to maintain a heightened clinical suspicion to avoid missed or delayed diagnosis of subtle fragility fractures. These fractures can occur without apparent mechanism (i.e., simple&#x000a0;transfer of a patient from bed-to-chair).&#x000a0; In the event that anti-osteoporosis medication has not been implemented or at least considered for these patients, the appropriate referrals should be made to the appropriate&#x000a0;physician or clinic. [Level II]</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26413.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26413&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26413">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/joint-muscle-and-bone/osteoporosis-in-spinal-cord-injuries/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=26413">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26413/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26413">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-26413.s17">
        <title>References</title>
        <ref id="article-26413.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Varacallo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seaman</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Jandu</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Pizzutillo</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <chapter-title>Osteopenia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">29763053</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26413.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varacallo</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Osteoporosis and its complications.</article-title>
            <source>Med Clin North Am</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>98</volume>
            <issue>4</issue>
            <fpage>817</fpage>
            <page-range>817-31, xii-xiii</page-range>
            <pub-id pub-id-type="pmid">24994054</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26413.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Battaglino</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Lazzari</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Garshick</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Morse</surname>
                <given-names>LR</given-names>
              </name>
            </person-group>
            <article-title>Spinal cord injury-induced osteoporosis: pathogenesis and emerging therapies.</article-title>
            <source>Curr Osteoporos Rep</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>278</fpage>
            <page-range>278-85</page-range>
            <pub-id pub-id-type="pmid">22983921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26413.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <article-title>SCI facts and figures 2016.</article-title>
            <source>J Spinal Cord Med</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>39</volume>
            <issue>6</issue>
            <fpage>737</fpage>
            <page-range>737-738</page-range>
            <pub-id pub-id-type="pmid">27858586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26413.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <article-title>Spinal Cord Injury (SCI) Facts and Figures at a Glance.</article-title>
            <source>J Spinal Cord Med</source>
            <year>2016</year>
            <month>May</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>370</fpage>
            <page-range>370-1</page-range>
            <pub-id pub-id-type="pmid">27193177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26413.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frontera</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Mollett</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Aging with Spinal Cord Injury: An Update.</article-title>
            <source>Phys Med Rehabil Clin N Am</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>821</fpage>
            <page-range>821-828</page-range>
            <pub-id pub-id-type="pmid">29031346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26413.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Szollar</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Sartoris</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Parthemore</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Deftos</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Bone mineral density and indexes of bone metabolism in spinal cord injury.</article-title>
            <source>Am J Phys Med Rehabil</source>
            <year>1998</year>
            <season>Jan-Feb</season>
            <volume>77</volume>
            <issue>1</issue>
            <fpage>28</fpage>
            <page-range>28-35</page-range>
            <pub-id pub-id-type="pmid">9482376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26413.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gifre</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vidal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Carrasco</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Muxi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Portell</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Monegal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gua&#x000f1;abens</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Peris</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for the development of osteoporosis after spinal cord injury. A 12-month follow-up study.</article-title>
            <source>Osteoporos Int</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>26</volume>
            <issue>9</issue>
            <fpage>2273</fpage>
            <page-range>2273-80</page-range>
            <pub-id pub-id-type="pmid">25939310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26413.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ominsky</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Cardozo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>JQ</given-names>
              </name>
              <name>
                <surname>Ke</surname>
                <given-names>HZ</given-names>
              </name>
              <name>
                <surname>Bauman</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Sclerostin Antibody Reverses the Severe Sublesional Bone Loss in Rats After Chronic Spinal Cord Injury.</article-title>
            <source>Calcif Tissue Int</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>103</volume>
            <issue>4</issue>
            <fpage>443</fpage>
            <page-range>443-454</page-range>
            <pub-id pub-id-type="pmid">29931461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26413.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiang</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Osteoporosis after spinal cord injury.</article-title>
            <source>Osteoporos Int</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>180</fpage>
            <page-range>180-92</page-range>
            <pub-id pub-id-type="pmid">16217589</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26413.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marcu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bogdan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mu&#x00163;iu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Laz&#x00103;r</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The histopathological study of osteoporosis.</article-title>
            <source>Rom J Morphol Embryol</source>
            <year>2011</year>
            <volume>52</volume>
            <issue>1 Suppl</issue>
            <fpage>321</fpage>
            <page-range>321-5</page-range>
            <pub-id pub-id-type="pmid">21424070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26413.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sezer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Akku&#x0015f;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>U&#x0011f;urlu</surname>
                <given-names>FG</given-names>
              </name>
            </person-group>
            <article-title>Chronic complications of spinal cord injury.</article-title>
            <source>World J Orthop</source>
            <year>2015</year>
            <month>Jan</month>
            <day>18</day>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-33</page-range>
            <pub-id pub-id-type="pmid">25621208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26413.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barbeau</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ladouceur</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Norman</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>P&#x000e9;pin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leroux</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Walking after spinal cord injury: evaluation, treatment, and functional recovery.</article-title>
            <source>Arch Phys Med Rehabil</source>
            <year>1999</year>
            <month>Feb</month>
            <volume>80</volume>
            <issue>2</issue>
            <fpage>225</fpage>
            <page-range>225-35</page-range>
            <pub-id pub-id-type="pmid">10025502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26413.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bittar</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Cliquet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dos Santos Fl&#x000f6;ter</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Utility of quantitative ultrasound of the calcaneus in diagnosing osteoporosis in spinal cord injury patients.</article-title>
            <source>Am J Phys Med Rehabil</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>90</volume>
            <issue>6</issue>
            <fpage>477</fpage>
            <page-range>477-81</page-range>
            <pub-id pub-id-type="pmid">21765270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26413.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varacallo</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Hassenbein</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Warlow</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Patients' response toward an automated orthopedic osteoporosis intervention program.</article-title>
            <source>Geriatr Orthop Surg Rehabil</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>89</fpage>
            <page-range>89-98</page-range>
            <pub-id pub-id-type="pmid">24319621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26413.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Phuan-Udom</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lektrakul</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Katchamart</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>The association between 10-year fracture risk by FRAX and osteoporotic fractures with disease activity in patients with rheumatoid arthritis.</article-title>
            <source>Clin Rheumatol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>37</volume>
            <issue>10</issue>
            <fpage>2603</fpage>
            <page-range>2603-2610</page-range>
            <pub-id pub-id-type="pmid">30039267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26413.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alejandro</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Constantinescu</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>A Review of Osteoporosis in the Older Adult: An Update.</article-title>
            <source>Rheum Dis Clin North Am</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>437</fpage>
            <page-range>437-451</page-range>
            <pub-id pub-id-type="pmid">30001785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26413.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edwards</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Simonian</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Haider</surname>
                <given-names>IT</given-names>
              </name>
              <name>
                <surname>Anschel</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Gregory</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Parachuri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Troy</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Schnitzer</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Effects of Teriparatide and Vibration on Bone Mass and Bone Strength in People with Bone Loss and Spinal Cord Injury: A Randomized, Controlled Trial.</article-title>
            <source>J Bone Miner Res</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>33</volume>
            <issue>10</issue>
            <fpage>1729</fpage>
            <page-range>1729-1740</page-range>
            <pub-id pub-id-type="pmid">29905973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26413.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akkawi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Zmerly</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Osteoporosis: Current Concepts.</article-title>
            <source>Joints</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>122</fpage>
            <page-range>122-127</page-range>
            <pub-id pub-id-type="pmid">30051110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26413.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schnitzer</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yeasted</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Simonian</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Zoledronic Acid Treatment After Acute Spinal Cord Injury: Results&#x000a0;of a Randomized, Placebo-Controlled Pilot Trial.</article-title>
            <source>PM R</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>8</volume>
            <issue>9</issue>
            <fpage>833</fpage>
            <page-range>833-43</page-range>
            <pub-id pub-id-type="pmid">26828618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26413.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gordon</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Wald</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Schnitzer</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Effect of parathyroid hormone combined with gait training on bone density and bone architecture in people with chronic spinal cord injury.</article-title>
            <source>PM R</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>5</volume>
            <issue>8</issue>
            <fpage>663</fpage>
            <page-range>663-71</page-range>
            <pub-id pub-id-type="pmid">23558091</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26413.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiang</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>LY</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of osteoporosis in spinal cord injury.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>65</volume>
            <issue>5</issue>
            <fpage>555</fpage>
            <page-range>555-65</page-range>
            <pub-id pub-id-type="pmid">17054455</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
